The PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges

The phosphatidylinositol 3 kinase (PI3K) pathway is frequently altered in cancer, including ovarian cancer (OC). Unfortunately, despite a sound biological rationale and encouraging activity in preclinical models, trials of first-generation inhibitors of mammalian target of rapamycin (mTOR) in OC hav...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheaib, Bianca, Auguste, Aurélie, Leary, Alexandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sun Yat-sen University Cancer Center 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302085/
https://www.ncbi.nlm.nih.gov/pubmed/25556614
http://dx.doi.org/10.5732/cjc.014.10289

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302085/
https://www.ncbi.nlm.nih.gov/pubmed/25556614
http://dx.doi.org/10.5732/cjc.014.10289

Ejemplares similares